CLEVELAND – When Mike Mahoney took the helm of Boston Scientific Corp. in 2012, the company had little to no growth and was bogged down in litigation tied to its acquisition of Guidant Corp. The firm was also mainly focused on cardiovascular solutions. Fast forward to 2017 and the Marlborough, Mass.-based company has fully emerged from past turmoil. Mahoney spoke about Boston Scientific's turnaround in a fireside chat held on the second day of the Cleveland Clinic's 2017 Medical Innovation Summit.
CLEVELAND – The genomics field holds the key to providing critical insight and eliminating some of the most debilitating diseases. However, diagnostic companies in the space face significant hurdles to innovation via issues with reimbursement and costs to conduct clinical trials.
ATLANTA – Medovex Corp. has developed a device to help treat pain associated with facet joint syndrome. The Atlanta-based company's Denervex technology competes against intra-articular injections and radiofrequency ablation procedures that treat pain. Medovex received CE mark for the technology in June.
Optiscan Biomedical Corp. has received 510(k) clearance for its Optiscanner 5000 glucose monitoring system. The clearance allows the device to be used for monitoring plasma glucose levels and determining dysglycemia in surgical intensive care unit (ICU) patients.
Two years ago, my youngest child was just learning how to walk and analysts were praising Abbott Laboratories' bioresorbable vascular scaffold. Flash forward today - my son is riding his bike like a true champ (with training wheels) and Abbott is singing a different tune about bioresorbable stents. In fact, the Abbott Park Ill.-based company isn't singing any tunes about Absorb at all. Oh, what a difference two years can make. Earlier this month, Abbott announced that it was discontinuing sales of its Absorb stent - citing low sales as the reason. The news broke on a quiet Friday afternoon -...
